By 2030, it is anticipated that the Australia infectious disease therapeutics market will reach a value of $2.27 Bn from $1.44 Bn in 2022, growing at a CAGR of 5.9% during 2022-2030. Infectious Disease Therapeutics in Australia is dominated by domestic pharmaceutical companies such as AdAlta, Starpharma and CSL. The Infectious Disease Therapeutics market in Australia is segmented into different therapeutic areas and different diseases type. The major factors affecting the Australia infectious disease therapeutics market are the increasing disease burden of communicable diseases like TB, hepatitis, and COVID-19 and the amount of healthcare funding for infectious diseases treatment in various of areas of Australia.
By 2030, it is anticipated that the Australia infectious disease therapeutics market will reach a value of $2.27 Bn from $1.44 Bn in 2022, growing at a CAGR of 5.9% during 2022-2030.
Australia is a high-income developed country in Oceania bordering the Indian Ocean and the Southern Pacific Ocean. In Australia, the infectious disease market is an important healthcare sector that encompasses the prevention, diagnosis, and treatment of a variety of communicable diseases. Vaccines, antibiotics, antivirals, diagnostics, and other treatments are all part of this industry.
The Australian government has made significant investments in vaccine research and development, with agreements in place to procure doses of various vaccinations from companies such as Pfizer, Moderna, AstraZeneca, and Novavax. Australia's government spends 10.7% of its GDP on healthcare.
Market Growth Drivers Analysis
In comparison to many other nations, Australia has a very low frequency of infectious diseases; yet, the country has seen an upsurge in specific infections such as syphilis and gonorrhoea in recent years. Australia is geographically close to vibrant Asian economies, and it is also a member of the RCEP. It also has a high standard of living, with immigration fuelling population increase and disease prevalence. Antibiotics are the primary therapy for STIs, and the Australian government offers free or low-cost testing and treatment for these diseases. These aspects could boost Australia infectious disease therapeutics market.
Market Restraints
In Australia, the infectious disease therapies industry is frequently dominated by other pharmaceutical businesses as well as other treatment methods such as vaccines and antibiotics. Companies may find it challenging to obtain market share and generate significant commercial growth as a result of this. The Australian economy is still heavily reliant on Chinese consumption. There is a significant disparity among Australia's federated states. These factors may deter new entrants into the Australia infectious disease therapeutics market.
Key Players
February 2023: Tim Oldham, CEO and Managing Director of AdAlta Ltd joins Proactive's Elisha Newell to discuss the Yuuwa Capital wind-down. AdAlta Ltd has welcomed the backing of two venture capital fund investors, who will become important shareholders in the registry.
December 2022: CSL Seqirus, a subsidiary of CSL, announced the completion of its global collaboration and licence agreement with Arcturus Therapeutics Holdings. The agreement gives Arcturus Therapeutics access to its late-stage self-amplifying mRNA (sa-mRNA) vaccine platform technology, which recently reported results from a large COVID-19 Phase III vaccine efficacy study, meeting its primary and secondary endpoints of infection and severe disease prevention with a favourable safety and tolerability profile.
In Australia, the reimbursement and regulation of infectious illness treatments are primarily handled by the Therapeutic Goods Administration (TGA) and the Pharmaceutical Benefits Scheme (PBS). Following the completion of clinical trials, the pharmaceutical is examined by the Pharmaceutical Benefits Advisory Committee (PBAC) to determine its increased therapeutic value above existing treatments. The PBAC assesses the benefits and makes a recommendation to the Minister of Health.
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By Mode of Treatment (Revenue, USD Billion):
By Applications (Revenue, USD Billion):
By Disease Type (Revenue, USD Billion):
By Target Organism (Revenue, USD Billion):
By End User (Revenue, USD Billion):
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.
By 2030, it is anticipated that the Australian infectious disease therapeutics market will reach a value of $2.27 Bn from $1.44 Bn in 2022, growing at a CAGR of 5.9% during 2022-2030.
In Australia, the reimbursement and regulation of infectious illness treatments is primarily handled by the Therapeutic Goods Administration (TGA) and the Pharmaceutical Benefits Scheme (PBS).
Infectious Disease Therapeutics in Australia is dominated by a few domestic pharmaceutical companies such as AdAlta, Starpharma and CSL.